Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
作者： Antonio M. Gotto , Edwin Whitney , Evan A. Stein , Deborah R. Shapiro , Michael Clearfield
关键词: Cardiology 、 Apolipoprotein B 、 Cholesterol 、 Medicine 、 Sudden cardiac death 、 Coronary atherosclerosis 、 Unstable angina 、 Myocardial infarction 、 Cohort 、 Endocrinology 、 Internal medicine 、 Risk factor
摘要: Background—The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) is the first primary-prevention study in a cohort with average total cholesterol (TC) and LDL (LDL-C) below-average HDL (HDL-C). Treatment lovastatin (20 to 40 mg/d) resulted 25% reduction LDL-C 6% increase HDL-C, as well 37% risk for acute major coronary event (AMCE), defined fatal or nonfatal myocardial infarction, unstable angina, sudden cardiac death. This article describes relation between baseline on-treatment lipid apolipoprotein (apo) parameters subsequent AMCEs. Methods Results—With all available data from entire 6605-patient cohort, prespecified Cox backward stepwise regression model identified outcome predictors, logistic models examined variables AMCE risk. Baseline LDL-C, apoB were significant predictors of AMCE; only apoB...
sci-hub.se 参考文章(22)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels The New England Journal of Medicine. ,vol. 339, pp. 1349- 1357 ,(1998) , 10.1056/NEJM199811053391902
Tall Ar, An overview of reverse cholesterol transport. European Heart Journal. ,vol. 19, pp. 31- 35 ,(1998)
Gary L. Myers, Gerald R. Cooper, Carole L. Winn, S. Jay Smith, The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: An Approach to Accurate and Precise Lipid Measurements Clinics in Laboratory Medicine. ,vol. 9, pp. 105- 136 ,(1989) , 10.1016/S0272-2712(18)30645-0
M J Chapman, M Guérin, E Bruckert, Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. European Heart Journal. ,vol. 19, ,(1998)
Benoît Lamarche, André Tchernof, Pascale Mauriege, Bernard Cantin, Gilles R Dagenais, Paul J Lupien, Jean-Pierre Després, Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease JAMA. ,vol. 279, pp. 1955- 1961 ,(1998) , 10.1001/JAMA.279.24.1955
J. D. Neaton, Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group Archives of Internal Medicine. ,vol. 152, pp. 1490- 1500 ,(1992) , 10.1001/ARCHINTE.152.7.1490
Terje R. Pedersen, Anders G. Olsson, Ole Færgeman, John Kjekshus, Hans Wedel, Kåre Berg, Lars Wilhelmsen, Torben Haghfelt, Gudmundur Thorgeirsson, Kalevi Pyörälä, Tatu Miettinen, Bjørn Christophersen, Jonathan A. Tobert, Thomas A. Musliner, Thomas J. Cook, Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S) Circulation. ,vol. 97, pp. 1453- 1460 ,(1998) , 10.1161/01.CIR.97.15.1453
John R Downs, Polly A Beere, Edwin Whitney, Michael Clearfield, Stephen Weis, Jeffrey Rochen, Evan A Stein, Deborah R Shapiro, Alexandra Langendorfer, Antonio M Gotto, Design & Rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) American Journal of Cardiology. ,vol. 80, pp. 287- 293 ,(1997) , 10.1016/S0002-9149(97)00347-0
James D. Neaton, Serum Cholesterol Level and Mortality Findings for Men Screened in the Multiple Risk Factor Intervention Trial Archives of Internal Medicine. ,vol. 152, pp. 1490- 1500 ,(1992) , 10.1001/ARCHINTE.1992.00400190110021
S M Marcovina, V P Gaur, J J Albers, Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B. Clinical Chemistry. ,vol. 40, pp. 574- 578 ,(1994) , 10.1093/CLINCHEM/40.4.574